Peer Review History
| Original SubmissionOctober 28, 2021 |
|---|
|
PONE-D-21-34544Positive attitudes towards COVID-19 vaccines: A cross-country analysis.PLOS ONE Dear Dr. Rossouw, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Feb 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Prof. Anat Gesser-Edelsburg, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The article uses Big Data to study a very important topic of COVID-19 vaccine hesitancy and factors that may enhance vaccine uptake. The authors provide an expansive picture of commonalities and diversities among varied countries, which contribute to the understanding of this vital issue. The article is well-written, maintaining clarity and logical flow in the description of the findings and their potential value. Nonetheless, there are several elements that need to be improved in order for the article to be appropriate for publication, as follows: 1. The authors ‘mix’ between results and discussion. See section 4.1.2. the results should be presented as found, without the authors trying to provide an explanation to why each element was such found. These explanations (for example see lines 375-388 concerning Belgium or lines 389-396 concerning Netherlands) are not appropriate in the results section. 2. The authors should refrain from any judgmental comments (for example lines 395-396 – “It is safe to say that the information campaigns have paid off”). Scientific writing should state possible explanations to any phenomenon that is identified, usually based on previous publications or new theoretical hypotheses, but without any judgment of any kind (neither positive or negative). Furthermore, the authors have not shown any support that this is actually the case and that the information campaigns were the cause for the results identified; more cautious writing is recommended. The same relates to sentences such as line 467 “South Africa's woes are almost too many to count”. These types of phrases should be revised so that the sentence presents the finding as is and not referred to in ‘literary-type’ descriptions. 3. Whenever any assumption (or claimed ‘fact’) is written – it should be based on previously published data from scientific sources. Sentences such as “Australians have a deep-seated mistrust in their government officials, who seem to implement contradictory regulations across different states” (lines 398-399) have to be supported by such publications. 4. Lines 505-507 – “Compliance, the act of complying with government-mandated regulations to curb the spread of COVID506 19, is statistically significant and negatively related to the VPAI. Unwillingness to comply likely 507 motivates people to get vaccinated. “ is not clear. I would assume that compliance would follow positive attitudes (towards the vaccine or towards the authorized agencies). How do the authors explain the negative correlation? 5. The authors at times make claims that they do not show any support for based on their data. For example, their claim in lines 534-537 “This implies that, as the tweets related to vaccines increase, the attitude towards vaccines decreases. This may likely be because many of the tweets contain misinformation or conspiracy theories rather than campaigns and information to encourage being vaccinated - and, therefore, decreases positive attitudes towards vaccines.”. To support such a claim, they should check whether the tweets they investigated actually show this tendency. Reviewer #2: The results reported in the paper are interesting as such, since the topic of public reaction to the COVID-19 pandemic and the related interventions is a timely one. However, to this referee it seems that the descriptive interest of the results dominates over the analytical one, due to various technical issues, as detailed below. Why do authors call the analysis "panel analysis" when there is no panel of individuals followed at more than one time-point? Considering a country as an individual is a complicated assumption... In reality, the data is a sequence of cross-sectional analyses within each country without control of the relative media-related weight or publication frequency of pro- and anti-vax individuals in the data stream and therefore maybe biased as an estimate of the country specific sentiment... The analysis methods, common in econometric panel data analyses, have been devised for individual data and, as also commented upon above, have to be motivated for use on aggregated, non-individual, data... One could also suspect that people are more eager to announce an anti-vaccine stance than a neutral or pro-vaccine stance on social media, especially since the anti-vaxers are minorities, which therefore need more cohesion and solidarity... The paper also seems to conclude that a part of the negative opinions are more due to vaccine availability and related problems than to an "ideological" anti-vaccine stance. A clearer separation of these issues in the analysis, in addition to the VPAI2 index, would help the understanding of vaccine-related sentiment... In section 3.2.2 (Selection of covariates), many covariates are extracted from the same source as the response variable (the Tweet streams). Is there not a risk that this automatically induces correlations? In the equation (2, p13), one wonders what common monthly effect (lambda_m) is expected in different hemispheres, in countries in different phases of epidemic spread... The analysis in the paper is also to a large extent outdated, since so much , both in terms of restrictions and vaccinations, has happened since August '21... In case of revision, the authors should incorporate some recent material, either in the analysis or the discussion. Finally, regarding section 5 (Conclusions), a clearer distinction between conclusions strictly based on the analysis and authors opinions or suggestions for action should be made. Small language errors or typos to be corrected, e.g. "illicit" instead of "elicit" (p2 l36) or "By analysing, the latter..." (p7 l162) instead of "By analysing the latter..." This referee recommends a thorough revision and actualization of the paper before considering its possible publication. Reviewer #3: Manuscript Identification PONE-D-21-34544: This paper has two main objectives: 1) to conduct a cross-country panel analysis to investigate the trend in positive attitudes towards COVID-19 vaccines over time; and 2) lies with determining those variables which are significantly related to a positive vaccine attitude and can inform policymakers. The article has a good description of how previous studies analysed the emotions in vaccine-related tweets, and following this description, the authors present a considerable justification for why do this study, which is classified as the first study to use Big Data to determine the sentiment and emotions related to COVID-19 vaccines through a vaccine positive attitude index. The time series analysis is a good way to perform a point of view of this situation. The authors' proposal is to present an analysis based on tweets from 10 countries, also dividing the analysis into countries in the southern hemisphere and countries in the northern hemisphere. This choice is based on data availability, which can be considered a limitation of the study, in view of a non-characterization of how other countries could present differences regarding the information provided. Minor concerns The text of the paper needs to be revised as it has some inconsistencies regarding the information. 1. About Figure 1 - it is necessary to modify the dates of the years presented in this figure, considering that the data were collected in 2021, the years change according to the countries. In addition, I also suggest a review of the percentages presented in terms of the number of people fully vaccinated, which differ from Table 1. 2. Section 3.2.1: the authors present some illustrations based on word clouds generated by tweets and inform that this was done for all country but in the paper, it's possible to find just 2-word clouds showing information by Great Britain and South Africa. It's important to inform why just these 2 countries were present in this analysis. 3. Section 3.2.2: Scale 5c. In the second paragraph, the word complacency is not present. 4. The authors do not present the limitations of the study, an important point for future studies on the subject. In view of some methodological characteristics, my suggestion is to highlight some points such as: the translation of tweets in a non-English language; choice of countries based on data convenience and availability. 5. There is no specific topic in the study for discussing the data, however, in the description of the results, the authors present some references that can be considered part of this discussion of the data. As this is an analytical study, it would be important to have a more in-depth discussion, comparing the results to other previous studies. The manuscript has good methodological quality, is free of bias, needs some adjusts but the results are discussed based on the theoretical background properly of the manuscript theme. So, the conclusions answered the aims of the study focused on the references and results. The limitations of the study were not presented, and I suggest that this could be done. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: Yes: Leonardo Pestillo de Oliveira [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Positive attitudes towards COVID-19 vaccines: A cross-country analysis. PONE-D-21-34544R1 Dear Dr. Rossouw, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Prof. Anat Gesser-Edelsburg, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: (No Response) Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: (No Response) Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: (No Response) Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The article adds important input to readers; the authors appropriately modified the manuscript and addressed all comments Reviewer #2: The authors replied to all the reviewer's comments and edited the manuscript in various areas. The paper may be published as is, though some weaknesses remain, for example the debate on the representativeness of tweets to reflect the feelings of the general population, including those who do not use tweets. Reviewer #3: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No |
| Formally Accepted |
|
PONE-D-21-34544R1 Positive attitudes towards COVID-19 vaccines: A cross-country analysis. Dear Dr. Rossouw: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Prof. Anat Gesser-Edelsburg Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .